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Abstract
Antiphospholipid antibodies contribute to the development of thrombosis, although precise mechanisms remain to be elucidated.
We determined the effects of affinity-purified anti-beta2-glycoprotein 1 (anti-b2GP1) and anti-prothrombin (anti-PT) antibodies
on in vitro platelet aggregation. Adenosine diphosphate (ADP) and collagen-induced platelet aggregation were performed
using platelet-rich plasma ([PRP] 250  109/L). Antiphospholipid antibodies (1.25-10 mg/mL) were preincubated with PRP for
10 minutes at 37C prior to the addition of agonist. Anti-b2GP1 antibodies significantly reduced platelet aggregation (percentage
area under the curve; %AUC) in a concentration-dependent manner using both 5 mmol/L (P < .001) and 2.5 mmol/L (P¼ .038) ADP
but did not significantly affect the rate of aggregation. Anti-PT antibodies significantly enhanced 5 mg/mL collagen-induced platelet
aggregation (%AUC; P ¼ .034) but did not affect ADP-induced platelet aggregation. These results suggest (1) interactions and
effects of antiphospholipid antibodies on platelets are agonist and concentration dependent and (2) anti-b2GP1 antibodies may
inhibit dense granule release and/or inhibition of the arachidonic acid pathway.
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Introduction
Platelets help maintain hemostasis and are the first line of
defense against loss of blood following trauma. This is
achieved by adhesion, initial plug formation, activation, and
aggregation. Activation causes the expression of anionic phos-
pholipids on the platelet surface, the release of various hemo-
static and nonhemostatic substances from platelet granules,
and the initiation of the arachidonic acid pathway. The result-
ing production of thromboxane A2 (TxA2) in turn promotes fur-
ther platelet activation.
Antiphospholipid antibodies are a heterogeneous group of
immunoglobulins, including anti-cardiolipin (aCL) antibodies
and lupus anticoagulants (LAs), which target phospholipids
and phospholipid-binding proteins. The major protein targets
of antiphospholipid antibodies are beta2-glycoprotein 1
(b2GP1) and prothrombin (PT),
1 although there are a wide
range of other hemostatic proteins that have been described and
investigated.2-5
Patients with antiphospholipid antibodies, for example, the
antiphospholipid syndrome (APS) and systemic lupus erythe-
matosus (SLE), are at a higher risk of thrombosis,6,7 although
precise mechanisms remain unclear. Indeed, there are conflict-
ing reports on the interactions between antiphospholipid anti-
bodies and platelets. It has previously been reported that
platelet hyperfunction (as measured by platelet aggregation)
is present in patients with antiphospholipid antibodies,8 sug-
gesting an important role for platelets in the development of
thrombosis in these patients. Furthermore, it has been
demonstrated that aCL and/or LA from patients with SLE bind
to several platelet membrane proteins, for example, platelet
glycoprotein IIIa, suggesting that antiphospholipid antibodies
may contribute to mediating platelet activation.9,10 In
contrast, prolonged bleeding times (as a marker of primary
hemostasis), but without a bleeding phenotype, have been
reported in patients with antiphospholipid antibodies,11,12
instead suggesting these antibodies dampen rather than
increase platelet function.
Thus, the aim of this study was to investigate the effects of
the antiphospholipid antibodies, anti-b2GP1 and anti-PT, on plate-
let activation and aggregation, using in vitro platelet aggregation.
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Sample Preparation and Processing
Whole blood (9 parts) from healthy volunteers was collected in
3.8% sodium citrate (1 part) with minimal stasis using vacutai-
ners (Vacuette, Greniner Bio-One, GmbH, Austria). All
volunteers had not taken aspirin or other antiplatelet medica-
tions in the previous 10 days and had avoided foods known to
affect platelet aggregation, consistent with the previous work
of our group.13 Platelet-rich plasma (PRP) was obtained follow-
ing centrifugation for 10 minutes at 150g at 20C. Platelet-poor
plasma (PPP) from the same samples was prepared following fur-
ther centrifugation for 20 minutes at 2000g at 20C. Platelet counts
were performed on PRP using a blood analyser (Sysmex XS
1000i, Sysmex America Inc, Mundelein, IL, USA) and adjusted
to 250 109/L for each experiment using PPP from the same nor-
mal donor. Testing of platelets was completed within 3 hours.
Effect of Antiphospholipid Antibodies on Platelet
Aggregation
Platelet aggregation using light transmission aggregometry was
performed using a 4-channel AggRAM module (Helena
Laboratories, Beaumont, TX, USA). Adenosine diphosphate
(Sigma-Aldrich, Sydney, Australia) and equine collagen
(Helena Laboratories, Beaumont, TX, USA) were used as ago-
nists. 200 mL of PRP was incubated for 10 minutes at 37C with
25 mL of affinity-purified polyclonal anti-b2GP1 or anti-PT
(rabbit anti-human antibodies; Hyphen-Biomed, Neuville-
Sur-Oise, France; final concentrations 10 to 1.25 mg/mL). All
experiments were performed in duplicate and in parallel with
a duplicate of PRP incubated with 25 mL of buffered normal
saline ([BNS] pH 7.1) that was used as the baseline. Aggrega-
tion was initiated upon the addition of 25 mL of agonist (5 or
2.5 mmol/L ADP; 5 or 2.5 mg/mL collagen; final concentra-
tions). Parameters including percentage area under the curve
(%AUC), slope, and percentage maximum aggregation
(%Max) of samples were generated by the aggregometer soft-
ware (HemoRAM 1.1.0., Helena Laboratories). Test results
were compared to the baseline control run in conjunction with
each sample and results for all parameters measured were
recorded as the mean difference between the test and baseline.
Platelet-rich plasma used for test and baseline control runs
were from the same donor for each experiment.
Statistical Analysis
All figures were generated using GraphPad Prism 5 (Intuitive
Software for Science, San Diego, California). STATA version
10.0 (Statacorp LP, College Station, TX, USA) was used to
analyze platelet aggregation with a general linear model to test
for any differences between the baseline parameters and the
antibody results. Postestimation Holm test analysis was then
used to adjust P values for multiple comparisons. Results for
platelet aggregation are expressed as the mean difference from
baseline + standard error of the mean (SEM). For all analyses
P values less than .05 were considered statistically significant.
Results
Results for %AUC and %Max were similar for all experiments,
thus only %AUC data are presented.
Effect of Antiphospholipid Antibodies on ADP-Induced
Platelet Aggregation
Anti-b2GP1 antibodies inhibited ADP-induced aggregation in a
concentration dependent manner (typical platelet aggregation
traces are presented in Figure 1). Anti-b2GP1 antibodies signif-
icantly reduced %AUC in a concentration-dependent manner
when incubated with normal platelets induced by both
5 mmol/L and 2.5 mmol/L ADP (P < .001 and P ¼ .038; Figure
2A and B). There was no significant difference in the primary
slope of aggregation for platelets incubated with anti-b2GP1
antibodies (P > .05; Figure 2C and D). There was no significant
difference or concentration-dependent response in platelet
aggregation (both %AUC and slope) in platelets incubated with
anti-PT antibodies when induced by either 5 mmol/L or
2.5 mmol/L ADP (Figure 3).
Effect of Antiphospholipid Antibodies on
Collagen-Induced Platelet Aggregation
Anti-b2GP1 antibodies significantly enhanced %AUC induced
by 2.5 mg/mL (P ¼ .018; Figure 4B) but not 5 mg/mL (Figure
4A) collagen. There was a significant difference in the rate
of aggregation (secondary slope) using 2.5 mg/mL (P ¼ .018;
Figure 4D) but not 5 mg/mL (Figure 4C) collagen. Anti-PT anti-
bodies significantly enhanced %AUC when induced by 5 mg/
mL (P ¼ .028; Figure 5A) but not 2.5 mg/mL (Figure 5B)
collagen. There was a significant difference in the rate of
aggregation (secondary slope) using 2.5 mg/mL (P ¼ 0.018;
Figure 5D) but not 5 mg/mL (Figure 5C) collagen.
Discussion
This study demonstrated that affinity-purified anti-b2GP1 and
anti-PT have variable effects on in vitro platelet aggregation.
The effects were dependent on the type and concentration of
agonist used, as well as the type of antiphospholipid antibody.
Furthermore, it was clearly and consistently demonstrated that
anti-b2GP1 antibodies significantly reduced in vitro ADP-
induced platelet aggregation in a concentration-dependent
manner.
It is interesting to speculate how ADP-induced platelet
aggregation may be inhibited by anti-b2GP1 antibodies.
ADP induces platelet aggregation by binding to the G-
protein-coupled receptors, P2Y1 and P2TAC, that are located
on platelet membranes.14 This leads to the inhibition of ade-
nyl cyclase, exposure of fibrinogen receptors, and the acti-
vation of phospholipase enzymes that metabolize
phosphatidylinositol to activate the arachidonic acid path-
way. Direct inhibition of these receptors may potentially
impede phospholipase C production, leading to decreased
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arachidonic acid and TxA2 production. The results from our
study, however, demonstrate that the rate (slope) of aggre-
gation was not affected, suggesting that anti-b2GP1 antibo-
dies do not affect primary aggregation but rather impede the
secondary aggregation mechanism. This is consistent with
previous work that has demonstrated ADP-induced primary
aggregation occurs independently of phospholipase C-
induced phosphatidylinositol metabolism.15,16 It may instead
be that anti-b2GP1 antibodies inhibit secondary aggregation
by impairing the release of dense granule contents, for
example, ADP, adenosine triphosphate (ATP), and seroto-
nin, as well as TxA2 production, during anti-b2GP1-spiked
ADP-induced platelet aggregation.
A further explanation for the data in the present study may
be that anti-b2GP1 antibodies enhance the modulating effect
of its target protein, b2GP1. It has previously been reported
that a possible in vitro function of b2GP1 is the inhibition
of ADP-induced aggregation, by interfering with the release
reaction of dense granules.17 It was demonstrated that
concentrations of b2GP1 greater than 0.1 mg/mL inhibited
serotonin release from platelets using ADP concentrations
from 2 mmol/L to 10 mmol/L but did not affect collagen-
or thrombin-induced aggregation. Whether the binding of
anti-b2GP1 antibodies to b2GP1 inhibits the release of other
important platelet activation agents, such as ADP and cal-
cium ions, from platelet-dense granules remains to be
determined.
In contrast to the ADP results, the effects of antiphospholi-
pid antibodies on collagen-induced platelet aggregation were
significantly more variable. Collagen stimulates irreversible
in vitro platelet aggregation by binding to glycoprotein
membrane receptors Ia/IIa (GP Ia/IIa) and VI (GP VI), inducing
changes in shape and exposure of membrane phospholipids.18
Low concentrations of collagen (1-2 mg/mL) stimulate platelet
aggregation through mechanisms dependent on the arachidonic
pathway and subsequent TxA2 synthesis. Alternatively, high
concentrations of collagen can induce aggregation by directly
increasing calcium concentrations, thus releasing the contents
Figure 1. Representative traces demonstrating the effect of anti-beta2-glycoprotein 1 (anti-b2GP1) antibodies on ADP-induced platelet aggre-
gation. Channels 1 and 3: platelet-rich plasma (PRP) þ 10 mmol/L anti-b2GP1. Channels 2 and 4: PRP þ buffer. A, 5 mmol/L adenosine dipho-
sphate (ADP). B, 2.5 mmol/L ADP.
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Figure 2. Effect of anti-beta2-glycoprotein 1 (anti-b2GP1) antibodies on adenosine diphosphate (ADP)-induced platelet aggregation. Dotted line
at mean difference %Max ¼ 0 represents baseline (platelet-rich plasma [PRP] with only buffer added). Percentage area under the curve (%AUC)
was significantly inhibited by anti-b2GP1 antibodies in a concentration-dependent manner. A, 5 mmol/L adenosine diphosphate (ADP). B,
2.5 mmol/L ADP. The rate of aggregation (slope) was not significantly affected by anti-b2GP1 antibodies. C, 5 mmol/L ADP. D, 2.5 mmol/L ADP.
Data presented as mean + standard error of the mean ([SEM] n ¼ 12-23).
Figure 3. Effect of anti-prothrombin (anti-PT) antibodies on adenosine diphosphate (ADP)-induced platelet aggregation. Dotted line at mean
difference percentage maximum aggregation (%Max) ¼ 0 represents baseline (platelet-rich plasma [PRP] with only buffer added). Percentage
area under the curve (%AUC) and slope were not significantly altered by anti-PT antibodies. A and C, 5 mmol/L ADP. B and D, 2.5 mmol/L ADP
(n ¼ 10-21).
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Figure 4. Effect of anti-beta2-glycoprotein 1 (anti-b2GP1) antibodies on collagen-induced platelet aggregation. Dotted line at mean difference
percentage maximum aggregation (%Max) ¼ 0 represents baseline (platelet-rich plasma [PRP] with only buffer added). Percentage area under
the curve (%AUC; 2.5 mg/mL but not 5 mg/mL collagen) was significantly enhanced by anti-b2GP1 antibodies. A, 5 mg/mL collagen. B, 2.5 mg/mL
collagen. Similarly, the rate of aggregation (slope; 2.5 mg/mL but not 5 mg/mL collagen) was significantly enhanced by anti-b2GP1 antibodies. C,
5 mg/mL collagen. D, 2.5 mg/mL collagen (n ¼ 3).
Figure 5. Effect of anti-prothrombin (anti-PT) antibodies on collagen-induced platelet aggregation. Dotted line at mean difference percentage
maximum aggregation (%Max) ¼ 0 represents baseline (platelet-rich plasma [PRP] with only buffer added). Percentage area under the curve
(%AUC; 5 mg/mL but not 2.5 mg/mL collagen) was significantly enhanced by anti-PT antibodies. A, 5 mg/mL collagen. B, 2.5 mg/mL collagen. The
rate of aggregation (slope) was not significantly affected by anti-PT antibodies. C, 5 mg/mL collagen. D, 2.5 mg/mL collagen (n ¼ 3).
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of alpha and dense granules. How collagen-induced platelet
aggregation was enhanced by both anti-b2GP1 and anti-PT
antibodies used in this study is unclear, however they may
bind to collagen-dependent receptors to stimulate further
aggregation. It has previously been proposed that complexes
of b2GP1-anti-b2GP1 may bind to negatively charged phos-
pholipids that become exposed following activation and
interact with the apolipoprotein ER2 receptor, resulting in
platelets becoming more sensitive to the effects of collagen
and subsequent platelet activation.19 It may also be possible
that complexes of PT dimers, PT-anti-PT, or anti-PT alone
may interact with collagen-dependent mechanisms, where
it has been reported that PT dimers have increased affinity
for phospholipids.20
It has been well described that antiphospholipid antibo-
dies, particularly anti-b2GP1, are associated with hypercoa-
gulability and thrombotic complications.19-22 The results
from our present study instead suggest that anti-b2GP1 anti-
bodies may reduce hypercoagulability by inhibiting ADP-
induced platelet aggregation. It is known that a significant
proportion of patients with antiphospholipid antibodies
demonstrate a prolonged bleeding time (reflecting impaired
platelet function) without an accompanying bleeding pheno-
type,11,12 thus it may be that anti-b2GP1 antibodies play an
important role in dampening the platelet response in at least
a proportion of these patients.
In conclusion, this study demonstrated that affinity-
purified antiphospholipid antibodies, anti-b2GP1 and anti-
PT, have variable effects on in vitro platelet aggregation.
It is clear that anti-b2GP1 antibodies generate a
concentration-dependent inhibitory effect that reduces over-
all (%AUC), but not the rate (slope) of the primary wave of
ADP-induced aggregation. Further studies are warranted to
determine the precise interactions and thus the role of anti-
phospholipid antibodies in platelet function. Whether the in
vitro effects demonstrated here are also significant in vivo
remains to be determined. Finally, further investigation into
the response of platelets to other agonists such as thrombin,
TxA2, and arachidonic acid may provide further insight into
the direct mechanisms involved in antiphospholipid anti-
body interactions with platelets.
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